Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

by divibasicbldev | Nov 9, 2023 | Press Releases

— Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of ALS —- Fully humanized anti-α5β1 monoclonal antibody is ready for manufacture and IND-enabling studies —...

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

by divibasicbldev | Sep 14, 2023 | Press Releases

Purchases All 5,323,451 Shares Validly Tendered at $0.70 per SharePALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on...

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

by divibasicbldev | Sep 7, 2023 | Press Releases

— Attendees may request 1 x 1 meeting with management at [email protected] — PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a...

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function

by divibasicbldev | Aug 1, 2023 | Press Releases

— PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) — — Lead α5/β1 integrin drug candidate to be selected in H2 2023 — PALO ALTO, Calif. and...

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

by divibasicbldev | Jul 20, 2023 | Press Releases

Tender Offer Expected to Close Third Quarter of 2023PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery,...